U.S. Markets close in 5 hrs 54 mins

Nephros, Inc. (NEPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.91-0.16 (-1.98%)
As of 9:43AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.07
Open7.91
Bid7.68 x 900
Ask8.09 x 800
Day's Range7.91 - 8.07
52 Week Range5.08 - 10.00
Volume2,065
Avg. Volume16,590
Market Cap78.721M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.52
Earnings DateMar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.83
  • Nephros Announces Preliminary Results for First Quarter of 2021
    GlobeNewswire

    Nephros Announces Preliminary Results for First Quarter of 2021

    Anticipates Net Revenue of $2.7 Million; Highest First Quarter in Company History SOUTH ORANGE, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced preliminary results for the first quarter of 2021. Revenue for the quarter ended March 31, 2021 is expected to be $2.7 million, representing growth of 17% over the prior period, and 8% over the same period in 2020. “Despite the pandemic, Nephros accomplished a milestone, recording the highest ever, first-quarter revenue, and the third-highest quarterly revenue in our history. These results, represented by strength in all of our filtration markets – Healthcare, Dialysis, and Commercial – reflect the growth of our underlying business and steady, long-term focus on taking care of our strategic partners and customers,” said Andy Astor, Chief Executive Officer of Nephros. “As more of the country is vaccinated over the coming weeks and months, we anticipate increasingly open markets and a return to pre-pandemic growth rates.” Nephros ended the first quarter with approximately $8.1 million in cash on a consolidated basis. Nephros will announce its first-quarter results on Thursday, May 6, 2021 and will host a conference call that same day at 4:30 PM ET. About Nephros Nephros is a leading water technology company in medical and commercial water purification and pathogen detection, headquartered in the USA. Our diverse team of passionate employees is dedicated to advancing point-of-use water safety through education, product solutions, and emergency outbreak response management. For more information about Nephros, please visit www.nephros.com. Forward-Looking Statements This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’s expected revenue for the quarter ended March 31, 2021, expected future growth and the timing of such growth and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including the impact of the ongoing COVID-19 pandemic, uncertainty in clinical outcomes, potential delays in the regulatory approval process, changes in business, economic and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers and researchers, regulatory reforms, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros’s reports filed with the U.S. Securities and Exchange Commission. Nephros does not undertake any responsibility to update the forward-looking statements in this release. Investor Relations Contacts: Kirin Smith, PresidentPCG Advisory, Inc.(646) 823-8656ksmith@pcgadvisory.com Andy Astor, CEONephros, Inc.andy@nephros.com(201) 345-0824

  • Nephros to Present at the Q1 Virtual Investor Summit
    GlobeNewswire

    Nephros to Present at the Q1 Virtual Investor Summit

    SOUTH ORANGE, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that Andy Astor, Chief Executive Officer, has been invited to present at the Q1 Virtual Investor Summit. The conference will take place on March 23-25, 2021, and includes a Nephros company presentation and Q&A at 2:30 p.m. ET on March 23. To register to attend the live presentation click the following link: https://zoom.us/webinar/register/WN_rBYVMLR8RP6-JbQsQa1qOQ To request a complimentary investor registration and 1-to-1 meeting with Nephros, please visit the conference website at www.investorsummitgroup.com. About Nephros Nephros is a leading water technology company in medical and commercial water purification and pathogen detection, headquartered in the USA. Our diverse team of passionate employees are dedicated to advancing point-of-use water safety through education, product solutions, and emergency outbreak response management. For more information about Nephros, please visit www.nephros.com. About The Investor Summit The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting small-cap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors. Conference Contact: Brittney Blocker at brittney@investorsummitgroup.com Investor Relations Contact:Kirin Smith, PresidentPCG Advisory, Inc.(646) 823-8656ksmith@pcgadvisory.comwww.pcgadvisory.com Company Contact:Andy Astor, President and CEONephros, Inc.(201) 345-0824andy@nephros.comwww.nephros.com Wire Service ContactInvestorWire (IW) Los Angeles, Californiawww.InvestorWire.com212.418.1217 OfficeEditor@InvestorWire.com